Biogen's Q2 Earnings & Sales Beat, 2025 Outlook Raised, Stock Up

Biogen (BIIB) reported robust Q2 2025 results, with adjusted EPS of $5.47 and revenues of $2.65 billion significantly beating Zacks Consensus Estimates of $3.93 and $2.32 billion respectively, propelled by strong performance from new drugs like Leqembi, Vumerity, and Zurzuvae. Despite revenue declines in established MS drugs due to generic competition, the company raised its full-year 2025 adjusted EPS guidance to $15.50-$16.00 (from $14.50-$15.50) and upgraded its revenue outlook to flat from a prior mid-single-digit decline. This positive shift, driven by the new product portfolio, boosted investor confidence, leading to a pre-market stock increase exceeding 5%.

Analysis

Biogen's second-quarter results demonstrated significant operational outperformance, with adjusted EPS of $5.47 and revenue of $2.65 billion substantially beating consensus estimates of $3.93 and $2.32 billion, respectively. This performance indicates a successful strategic pivot where robust growth from the new product portfolio is beginning to overshadow the secular decline in legacy assets. Specifically, new drugs like Vumerity (sales up 30% year-over-year to $212.2 million), Zurzuvae (up 68% sequentially to $46.4 million), and the Alzheimer's treatment Leqembi showed strong sequential growth, contributing to a 7% year-over-year rise in total revenue. This growth successfully counteracted the ongoing erosion in the Multiple Sclerosis (MS) franchise, where revenues fell 4% to $1.1 billion due to generic and biosimilar competition. The most critical development is the upward revision of full-year 2025 guidance; revenue is now projected to be flat versus a prior forecast of a mid-single-digit decline, and the adjusted EPS range was increased to $15.50-$16.00. This improved outlook, supported by cost discipline evidenced by a 13% drop in R&D expenses, suggests the company's growth inflection is arriving ahead of schedule.

Key Decisions for Investors

• The significant beat on earnings and sales, paired with a material upgrade to full-year 2025 guidance, suggests Biogen's turnaround is gaining traction faster than anticipated, warranting a reassessment of the stock for its growth potential.
• Investors should closely monitor the sales momentum of key new products—Leqembi, Skyclarys, and Zurzuvae—as their sustained growth is critical to offsetting the steeper declines now expected for the legacy MS business in the second half of the year.
• While the outlook has improved, the core risk remains execution-dependent; any slowdown in the commercial uptake of the new drug portfolio could jeopardize the company's ability to meet its revised, more optimistic targets.